What Is Neuroblastoma?

Neuroblastoma is a cancerous tumor found in young children and infants, most commonly in children under age 5 and rarely in those older than 10. Approximately 650 children in the United States are diagnosed with neuroblastoma each year. What causes neuroblastoma? The cause of neuroblastoma is not certain, but researchers believe it forms from neuroblasts, … Read more

What is a Benign Blood Disorder?

It might sound counterintuitive, but not every patient comes to Dana-Farber for cancer treatment. For example, the Institute’s experts regularly see patients seeking help with benign (non-cancerous) blood disorders. Benign blood disorders such as anemia and sickle cell disease are often treated at cancer centers because such institutions are home to experts in hematology, which … Read more

What is an Angiogenesis Inhibitor and How Can It Be Used to Treat Cancer?

Tumors can’t grow any larger than the size of a pinhead unless the body generates a network of new blood vessels to nourish them – a process known as angiogenesis. So using drugs called angiogenesis inhibitors to block this process is an ingenious strategy with many potential advantages over standard chemotherapy. Indeed, when the first … Read more

For the Freis, Dana-Farber Has Always Been Family

by Lauren Emily Frei When I married my husband, Emil Frei IV, in 1992, I knew I was entering into a large family. I just didn’t realize how large – until the first time I walked in the doors of Dana-Farber Cancer Institute. My father-in-law, Dr. Emil “Tom” Frei III, was physician-in-chief at Dana-Farber, which … Read more

Advice for Parenting During Cancer Treatment

Parents face many unique challenges when diagnosed with cancer. Perhaps one of the biggest hurdles is learning how to communicate with children about this difficult and emotional subject. In this Cancer Conversations podcast episode, Kelly Drummond, LICSW, a Dana-Farber social worker joins Dana-Farber social worker Allison Dibiaso, LICSW, and Sarah Silvia, a single mom who … Read more

A New Class of Cancer Drug Moves Closer to Potential FDA Approval in Leukemia

Updated April 13, 2015 Venetoclax, a new type of cancer drug known as a Bcl-2 inhibitor, is showing great promise against a poor-prognosis form of chronic lymphocytic leukemia (CLL), and could work in other cancers as well. Venetoclax, formerly known as ABT-199, attacks the protein molecule, Bcl-2, that allows cancer cells to survive despite signals … Read more

Immunotherapy, Targeted Drugs, Brain Cancer Research Among Highlights at Cancer Meeting

Eagerly awaited new data from trials of immunotherapy drugs, vaccines to treat brain tumors, and improved treatments for blood cancers sparked waves of optimism at the year’s biggest cancer meeting. The 2015 annual meeting of the American Society of Clinical Oncology (ASCO) drew about 30,000 cancer specialists to Chicago May 29 – June 2. Immunotherapy, … Read more